Group items tagged

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

This division of Ind Swift aspires to help those who cannot afford costly branded medicines. It is further divided into Agile, Maxcare and Health Care divisions which include a vast array of over 500 products from various therapeutic segments namely Antibiotic, Anti-Infectives, Anti-Cold, Nutraceuticals, Anti-Convulsants, Analgesics, Anti-Diarrhoeal, Anti-Allergics, Anti-Inflammatory and Anti-Ulcer Drugs, Hypolipidaemic Drugs, Anti Malarial, Enzyme, Expectorants, Antipsychotics & Anti-Depressants.

Indswift today is a renowned name among lakhs of employees of railways, armed forces, police force & paramilitary organizations. With the help of our Institution division we are able to cater to smallest & biggest government dispensaries, hospitals and remote and rural areas in India.

The global medical image analysis market is growing at a higher rate as compared to the equipment market. The image analysis software market is driven by higher demand for diagnostic procedures globally, technology improvements and demand from the consumer end. The major restraints are the inherent drawbacks associated with software. The major trends seen in the market are towards open source software, online portals and 30 day trials for software. The major challenges from the end-users are restriction in terms of software usage and major challenge for standalone vendors is the OEM manufacturers.